Abstrakt
Deltorfiny są peptydami wyizolowanymi ze skóry amazońskich żab. Chociaż zostały wyizolowane ponad 20 lat temu, są one nadal najsilniejszymi i najbardziej selektywnymi dostępnymi agonistami receptora δ-opioidowego. Potęgują uwalnianie dopaminy w dopaminowym układzie mezolimbicznym i są zaangażowane w nagradzające efekty wielu nadużywanych substancji. Aktywność deltorfin obejmuje również zależny od dawki stereotypowy wzór aktywności lokomotorycznej, efekt antynocyceptywny, wpływ na temperaturę ciała i działanie antydepresyjne w teście wymuszonego pływania u szczurów. Zatem deltorfiny są obiecującym celem w rozwoju terapii różnych chorób, włączając depresję.
Bibliografia
1. Bie B., Zhu W., Pan Z. Z.: Ethanol-induced delta-opioid receptor modulation of glutamate synaptic transmission and conditioned place preference in central amygdala. Neuroscience, 160, 348, 2009.
2. Bilsky E. J., Motegut M. J., Delong C. L., Reid L. D.: Opioidergic modulation of cocaine conditioned place preferences. Life Sci., 50, 85, 1992.
3. Broccardo M., Importa G.: Antidiarrheal and colonic antipropulsive effects of spinal and supraspinal administration of the natural delta opioid receptor agonist [D-Ala˛]-deltorphin II, in the rat. Eur. J. Pharmacol., 218, 69, 1992.
4. Chen X. H., Geller E. B., de Riel J. K. et al.: Antisense oligodeoxynucleotides against mu- or kappa-opioid receptors block agonist-induced body temperature changes in rats. Brain Res., 688, 237, 1995.
5. Cheng P. Y., Wu D., Decena J. et al.: Opioid-induced stimulation of fetal respiratory activity by [D-Ala˛]-deltorphin I. Eur. J. Pharmac., 230, 85, 1993.
6. Degli Uberti E. C., Salvadori S., Trasforini G. et al.: Delta-opioid receptors and the secretion of growth hormone in man: effect of δ-receptor agonist. Neuroendocrinology, 56, 907, 1992
7. Geller E. B., Hawk C., Keinat h S. H. et al.: Subclasses of opioids based on body temperature change in rats: acute subcutaneous administration. J. Pharmacol. Exp Ther., 225, 391, 1983.
8. Gyires KAZR, Toth G., Darula Z., Furst S.: Analysis of the role of delta opioid receptors in gastroprotection in the rat. Life Sci., 60, 1337, 1997.
9. Handler C. M., Geller E. B., Adler M. W.: Effect of mu-, kappa-, and delta-selective opioid agonists on thermoregulation in the rat. Pharmacol. Biochem. Behav., 43, 1209, 1992.
10. Hepburn M. J., Little P. J., Gingras J., Kuhn C. M.: Differential effects of naltrindole on morphine-induced tolerance and physical dependence in rats. J. Pharmacol. Exp. Ther., 281, 1350, 1997.
11. Herz A.: Opioid reward mechanisms: a key role in drug abuse? Can. J. Pharmac., 76, 252, 1998.
12. Holaday J. W., Long J. B., Tortella F. C.: Evidence for κ, μ and δ opioid binding site interactions in vivo. Fed. Proc., 44, 2851, 1985.
13. Hutcheston M. D., Matthes H. W. D., Valjent E. et al.: Lack of dependence and rewarding effects of deltorphin II in mu-opioid receptor-deficient mice. Eur. J. of Neurisci., 13, 153, 2001.
14. Improta T. G., Broccardo M.: Effect of selective mu1, mu2 and delta2 opioid receptor agonists on gastric functions in the rat. Neuropharmacolgy, 33, 977, 1994.
15. Jiang Q., Mosberg H., P o rr e c a F.: Antinociceptive effects of [D-Ala˛] deltorphin II, a highly selective delta agonist in vivo. Life Sci., 47, 43, 1990.
16. Kreil G., Barra D., S i m m a c o M. et al.: Deltorphin, a novel amphibian skin peptide with high selectivity and affinity for δ-opioid receptors. Eur. J. Pharmacol., 162, 123, 1989.
17. Lazarus H. L., Bryant S. D., Cooper P. S., Salvadori S.: What peptides these deltorphins be. Progress in Neurobiol., 57, 377, 1999.
18. Ling G. S. F., Simantov R., Clark J. A., Pasternak G.W.: Naloxonazine actions in vivo. Eur. J. Pharmacol., 129, 33, 1986.
19. Longoni R., Spina L., Mulas A. et al.: [D-Ala˛]deltorphin II: D1 dependent stereotypies and stimulation of dopamine release in the nucleus accumbens. J. Neurosci., 11, 1565, 1991.
20. Mankens K., Bilsky E., Wi l d K. et al.: Cocaine place preference is blocked by the δ-opioid antagonist, naltrindole. Eur. J. Pharmac., 219, 345, 1992.
21. Mansour A., Thompson R.C., Akil H., Watson S. J.: Delta opioid receptor mRNA distribution in the brain: comparison to delta receptor binding and proenkephalin mRNA. J. Chem. Neuroanat., 6, 351, 1993.
22. Mathlowitz E., Jacob J., Jong Y. et al.: Biologically erodable microspheres as potential oral drug delivery systems. Nature, 386, 410, 1997.
23. Matsuzawa S., Suzuki T., Misawa M., Nagase H.: Different roles of mu-, deltaand kappa-opioid receptors in ethanol-associated place preference in rats exposed to conditioned fear stress. Eur. J. Pharmacol., 368, 9, 1999.
24. Morgan M. M., Ashley M. D., Ingram S. L., C h r i s t i e M. J.: Behavioral consequences of delta-opioid receptor activation in the periaqueductal gray of morphine tolerant rats. Neural Plast., 2009 (doi: 10.1155/2009/516328).
25. Moulin D. E., Max M. B., Kaiko R. F. et al.: The analgesic efficancy of intrathecal D-Ala˛-D-Leu5-enkephalin in cancer patients with chronic pain. Pain, 23, 213, 1985.
26. Murakawa K., Hirose N., Takada K. et al.: Deltorphin II enhances extracellular levels of dopamine in the nucleus accumbens via opioid receptor-independent mechanisms. Eur. J. Pharmacol., 491, 31, 2004.
27. Negri L., Improta G., Lattanzi R. et al.: Interaction between the μ-agonist dermorphin and the δ-agonist D-Ala˛-Glu4] deltorphin in supraspinal antinociception and δ-opioid receptor binding. Br. J. Pharmacol., 116, 2931, 1995.
28. Negri L., Melchiorri P., Lattanzi R.: Pharmacology of Amphibian Opiate Peptides. Peptides, 21, 1639, 2000.
29. Negri L., Noviello L., F. Angelucci F.: Behavioral effects of deltorphins in rats. Eur. J. Pharmacol., 209, 163, 1991.
30. Patel D., Mc Kinley B. D., Davis T. P. et al.: Peptide targeting and delivery across the blood-brain barrier utilizing synthetic triglyceride esters: design, synthesis and bioactivity. Bioconjugate Chem., 8, 434, 1997.
31. Ruegg H., Yu W. Z., Bodnar R. J.: Opioid receptor subtype agonist-induced enhancement of sucrose intake are dependent upon sucrose concentration. Physiol. Behav., 62, 121, 1997.
32. Shimomura K., Kamata O., Ueki S. et al.: Analgesic effect of morphine glucuronides. Tohoku J. Exp. Med., 105, 45, 1971.
33. Suzuki T., Ikeda H., Tsuji M. et al.: Antisense oligodeoxynucleotide to δ opioid receptors attenuates morphine dependence in mice. Life Sci., 61, PL. 165, 1997.
34. Suzuki T., Mori T., Tsuji M. et al.: Differentia effects of μ-, - δ and κ-opioid receptor agonists on the discriminative stimulus properties of cocaine in rats. Eur. J. Pharmac., 324, 21, 1997.
35. Tomatis R., Marastoni M., Balboni G. et al.: Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J. Med. Chem., 40, 2948, 1997.
36. Torregrossa M. M., Jutkiewicz E. M., Mosberg H. I. et al.: Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res., 1069, 172, 2006.
37. Yu W. Z., Bodnar R. J.: Interactions between angiotensin II and delta opioid receptor subtype agonists upon water intake in rats. Peptides, 18, 241, 1997.
Praca jest udostępniana na licencji Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Prawa autorskie (c) 2009 Autor